Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Le Gouill, Steven; Thiéblemont, Catherine; Obéric, Lucie; Moreau, Anne; Bouabdallah, Krimo; Dartigeas, Caroline; Damaj, Gandhi; Gastinne, Thomas; Ribrag, Vincent; Feugier, Pierre; Casasnovas, Olivier; Zerazhi, Hacène; Haïoun, Corinne; Maisonneuve, Hervé; Houot, Roch; Jardin, Fabrice; Van Den Neste, Éric; Tournilhac, Olivier; Le Dû, Katell; Morschhauser, Franck; Cartron, Guillaume; Fornecker, Luc‐Matthieu; Canioni, Danielle; Callanan, Mary; C. Béné, Marie; Salles, Gilles; Tilly, Hervé; Lamy, T.; Gressin, Rémy; Hermine, Olivier

doi:10.1056/nejmoa1701769

Public

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Published in New England Journal of Medicine • Sep 27, 2017

Authors:

Steven Le Gouill

Catherine Thiéblemont

Lucie Obéric

Abstract

BACKGROUND: Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter of bo...

Subject

Mantle cell lymphoma

Medicine

Rituximab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!